Sarah A. Solomon is a partner in the firm’s Technology and Life Sciences groups. She currently serves as co-chair of Goodwin’s Women’s Initiative.

Ms. Solomon represents biotechnology, pharmaceutical, medical device and other life sciences companies in connection with their intellectual property, commercial and M&A transactions. She regularly advises private and public companies on complex strategic collaboration and partnering transactions (such as joint research and development agreements, co-commercialization agreements, patent licenses, strategic alliances and joint ventures); research, development and commercial relationships (such as manufacturing, supply, distribution, clinical trial, university and academic licenses and services agreements); and mergers and acquisitions (such as product acquisitions, spin-outs and structured M&A transactions). Ms. Solomon also counsels clients in connection with international transactions in North America, South America, Europe and Asia.





Strategic Alliances and Collaborations

  • Alnylam Pharmaceuticals in its transformational alliance with Genzyme for RNAi therapeutics as genetic medicines along with a $700 million equity investment
  • Alnylam Pharmaceuticals in its license and collaboration agreement with PeptiDream to discover and develop peptide-siRNA conjugates for targeted delivery of RNAi therapeutics, with a potential deal value of $2.2 billion in milestones
  • Alnylam Pharmaceuticals in its collaboration with Regeneron Pharmaceuticals for new RNA interference therapeutics focused on ocular and central nervous system diseases with deal value up to $1 billion
  • AMAG in its strategic collaboration with Endoceutics to develop and commercialize Intrarosa, with a potential deal value of up to $945 million
  • Arrakis Therapeutics in its strategic collaboration and license agreement with Roche for the discovery of RNA-targeted small molecule (rSM) drugs against a broad set of targets across all of Roche’s research and development areas, for $190 upfront
  • BeiGene in its global research and development collaboration with Ambrx to develop novel biologic drug products with aggregate value of up to $475 million
  • Blueprint Medicine in its worldwide collaboration with Roche for up to five small molecule kinase therapeutics for cancer immunotherapy; upfront of $45 million with total deal value of up to $965 million
  • BlueRock Therapeutics, a next-generation regenerative medicine company, in its $225 million financing by Bayer and Versant Ventures and seminal in-licenses and alliances with Memorial Sloan Kettering, the Centre for Commercialization of Regenerative Medicine and University Health Networks
  • ImmuNext in its exclusive, worldwide license with Sanofi to develop and commercialize a CD40L monoclonal antibody for use in autoimmune diseases, with potential deal value of up to $500 million, plus royalties
  • Immunometabolism Development Company in a licensing transaction with potential deal value of up to $605 million
  • Kymera Therapeutics in its strategic collaboration with Vertex to advance small molecule protein degraders against multiple biological targets, with potential deal value in excess of $1 billion
  • Kymera Therapeutics in its strategic partnership with Sanofi to advance novel protein degrader therapies, with potential deal value of over $2 billion, plus royalties
  • Moderna in its supply agreements for Moderna’s COVID-19 vaccine with governments around the world
  • Moderna in multiple strategic transactions with AstraZeneca, Merck and others with total upfront deal value in excess of $1 billion, plus downstream payments
  • Obsidian Therapeutics in its strategic collaboration with Celgene to develop novel, regulated cell therapies using Obsidian’s destabilizing domain technology
  • Radius Health in a global license agreement with the Menarini Group for the development and commercialization of Elacestrant, with a potential deal value of up to $350 million plus royalties
  • Scholar Rock in its strategic collaboration with Gilead to develop TGFβ inhibitors with potential total deal value of up to $1.5 billion
  • Schrödinger, Inc. in its collaboration and license agreement with Bristol Myers Squibb to discover, develop and commercialize therapeutics in multiple disease areas, with potential deal value of $2.7 billion, plus royalties
  • Schrödinger, Inc. in its collaboration with Zai Lab on a global R&D program in oncology
  • Surface Oncology in its strategic collaboration with Novartis to develop immunotherapeutics, with up to $170 million in near-term cash payments, plus milestones and royalties
  • Unum Therapeutics in its strategic collaboration and license agreement with Seattle Genetics to develop and commercialize ACTR therapies for cancer, with a total potential deal value of over $640 million, plus royalties
  • Wave Life Sciences in its global strategic collaboration with Takeda for nucleic acid therapies for CNS disorders, with potential deal value of over $2 billion 


  • BlueRock Therapeutics in its sale to Bayer AG for up to $1 billion
  • Nimbus in its long-term strategic alliance with Celgene to acquire two programs in immunology
  • Nimbus in its sale of Nimbus Apollo and its Acetyl-CoA Carboxylase (ACC) inhibitor program to Gilead Sciences for $400 million and up to an additional $800 million in development milestone payments
  • Noria Therapeutics and PSMA Therapeutics in their sale to Bayer
  • Promedior in its exclusive purchase option agreement with Bristol-Myers Squibb with potential deal value up to $1.25 billion
  • TARIS Biomedical in the sale of its lead product LiRIS to Allergan for a total potential deal value in excess of $580 million
  • TARIS Biomedical in its acquisition by Johnson & Johnson
  • ZOLL Medical in its sale to Asahi Kasei for $2.2 billion


Ms. Solomon has been recognized by The Best Lawyers in America Best Lawyers for her work in Biotechnology and Life Sciences Practice 2022. 

Ms. Solomon has been recognized as a leading life sciences attorney by The Best Lawyers in America, IAM Patent 1000, The International Who’s Who of Life Sciences Lawyers (Transactional), The Legal 500 United States (Intellectual Property - Patents: Licensing), and LMG Life Sciences (Licensing & Collaboration, Mergers & Acquisitions). In 2020, Ms. Solomon was nominated by LMG Life Sciences as “Licensing & Collaboration Attorney of the Year.”

In The News









J.D., 2001
University of California Hastings College of Law
B.S., Biology, 1996
University of California, San Diego



Profile Image
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.


Nos équipes interviennent aux côtés de nos clients, industriels, fonds d’investissement, startups, institutions financières et dirigeants, dans le cadre de transactions et de contentieux complexes, et apportent des conseils de tout premier plan dans les secteurs financiers, des Sciences de la Vie, du Private Equity, de l’immobilier et des technologies. Nous traitons les dossiers juridiques de manière intègre, ingénieuse, souple et audacieuse pour répondre efficacement aux enjeux propres à chacun de nos clients, quels que soient la taille de l’opération et le secteur d’activité. Pour en savoir plus, contactez-nous.

Unsere Kunden verlassen sich auf unsere erstklassige Beratung, vor allem im Hinblick auf komplexe Transaktionen und High-Stakes-Prozesse. Spezialisiert auf Angelegenheiten der Finanz-, Life-Sciences-, Private-Equity-, Immobilien-und Technologie-Branchen, verwenden wir einen kooperativen und interdisziplinären Ansatz, um Fragen unserer Kunden auch in extremen Spezialsituationen einer Lösung zuzuführen. Sie wollen mehr erfahren? Kontaktieren Sie uns gerne.

Search Other Lawyers
Recherche par Pratique